GuruFocus Updates (Free subscription) | 14/11/2009
By insider. Sr. Vice President and CFO of Medivation Inc. ( MDVN ) Clarence Patrick Machado sells 20,000 shares of MDVN on 11/11/2009 at an average price of $28.28 a share. Read more » »
PR News Wire (Free subscription) | 11/11/2009
SAN FRANCISCO, Nov. 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at Lazard Capital Markets Sixth Annual Healthcare conference on Wednesday, November 18, at 8:30 a.m. Eastern Time at the St. Regis Hotel in New York.
Red Orbit (Free subscription) | 04/11/2009
SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ -- Medivation, Inc.
PR News Wire (Free subscription) | 04/11/2009
SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the third quarter ended September 30, 2009.
Business Wire (Free subscription) | 03/11/2009
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon...
Medical News Today (Free subscription) | 05/11/2009
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
Life Science World (Free subscription) | 05/11/2009
[NEWS] — Company Received $110 Million Up-Front Payment from Astellas —— Conference Call Today at 4:30 p.m. Eastern Time — SAN FRANCISCO, Nov. 4 /PRNewswire-FirstCall/ — Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the third quarter ended September 30, 2009. “With the signing of our agreement for MDV3100...
PR News Wire (Free subscription) | 28/10/2009
SAN FRANCISCO, Oct. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2009 will be released after markets...
Fiercebiotech (Free subscription) | 27/10/2009
In just the latest sign of just how hot new cancer drugs have become, San Francisco-based Medivation garnered a $110 million upfront payment and a milestone package of $655 million from Astellas for global rights to its experimental prostate cancer drug. The therapy, MDV3100 , is currently being evaluated in the Phase III AFFIRM clinical trial in men with castration-resistant prostate cancer...
PR News Wire (Free subscription) | 27/10/2009
TOKYO and SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. ("Astellas") and Medivation, Inc. (Nasdaq: MDVN) announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in...
San Fransisco Chronicle (Free subscription) | 27/10/2009
Prostate drug - San Francisco's Medivation Inc. will receive a cash payment of $110 million from Astellas Pharma Inc. of Japan as part of a global agreement to develop and market MDV3100, Medivation's experimental drug for the treatment of prostate... Sponsored Topics: Cancer - Prostate cancer - San Francisco - Health - Conditions and Diseases
PR News Wire (Free subscription) | 26/10/2009
SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer.
The East Bay Business Times (Free subscription) | 27/10/2009
Medivation Inc.’s investigational prostate cancer drug could win the San Francisco company up to $765 million in a deal with Astellas Pharmaceuticals Inc. (MDVN)
The Street (Free subscription) | 27/10/2009
Japanese drugmaker Astellas buys worldwide rights to late-stage MDV-3100.
The Street (Free subscription) | 27/10/2009
Japanese drugmaker Astellas buys worldwide rights to late-stage MDV-3100.
